These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
179 related articles for article (PubMed ID: 9890156)
1. Human cytochrome P450s: selectivity and measurement in vivo. Smith DA; Abel SM; Hyland R; Jones BC Xenobiotica; 1998 Dec; 28(12):1095-128. PubMed ID: 9890156 [No Abstract] [Full Text] [Related]
2. Gemfibrozil is a potent inhibitor of human cytochrome P450 2C9. Wen X; Wang JS; Backman JT; Kivistö KT; Neuvonen PJ Drug Metab Dispos; 2001 Nov; 29(11):1359-61. PubMed ID: 11602509 [TBL] [Abstract][Full Text] [Related]
3. Inhibition of human CYP1A2 activity in vitro by methylxanthines: potent competitive inhibition by 8-phenyltheophylline. Murray S; Odupitan AO; Murray BP; Boobis AR; Edwards RJ Xenobiotica; 2001 Mar; 31(3):135-51. PubMed ID: 11465391 [TBL] [Abstract][Full Text] [Related]
4. Effect of chronic disulfiram administration on the activities of CYP1A2, CYP2C19, CYP2D6, CYP2E1, and N-acetyltransferase in healthy human subjects. Frye RF; Branch RA Br J Clin Pharmacol; 2002 Feb; 53(2):155-62. PubMed ID: 11851639 [TBL] [Abstract][Full Text] [Related]
5. Comparison of the substrate specificities of human liver cytochrome P450s 2C9 and 2C18: application to the design of a specific substrate of CYP 2C18. Minoletti C; Dijols S; Dansette PM; Mansuy D Biochemistry; 1999 Jun; 38(24):7828-36. PubMed ID: 10387023 [TBL] [Abstract][Full Text] [Related]
6. Homology modelling of human cytochromes P450 involved in xenobiotic metabolism and rationalization of substrate selectivity. Lewis DF Exp Toxicol Pathol; 1999 Jul; 51(4-5):369-74. PubMed ID: 10445400 [TBL] [Abstract][Full Text] [Related]
7. Lack of single-dose disulfiram effects on cytochrome P-450 2C9, 2C19, 2D6, and 3A4 activities: evidence for specificity toward P-450 2E1. Kharasch ED; Hankins DC; Jubert C; Thummel KE; Taraday JK Drug Metab Dispos; 1999 Jun; 27(6):717-23. PubMed ID: 10348802 [TBL] [Abstract][Full Text] [Related]
8. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: preferential inhibition of cytochrome P450 2C9 (CYP2C9). Wen X; Wang JS; Kivistö KT; Neuvonen PJ; Backman JT Br J Clin Pharmacol; 2001 Nov; 52(5):547-53. PubMed ID: 11736863 [TBL] [Abstract][Full Text] [Related]
9. In vivo modulation of CYP enzymes by quinidine and rifampin. Branch RA; Adedoyin A; Frye RF; Wilson JW; Romkes M Clin Pharmacol Ther; 2000 Oct; 68(4):401-11. PubMed ID: 11061580 [TBL] [Abstract][Full Text] [Related]
10. Interlaboratory comparison of the assessment of P450 activities in human hepatic microsomal samples. Boobis AR; McKillop D; Robinson DT; Adams DA; McCormick DJ Xenobiotica; 1998 May; 28(5):493-506. PubMed ID: 9622851 [TBL] [Abstract][Full Text] [Related]
11. Kinetic characterization and identification of the enzymes responsible for the hepatic biotransformation of adinazolam and N-desmethyladinazolam in man. Venkatakrishnan K; von Moltke LL; Duan SX; Fleishaker JC; Shader RI; Greenblatt DJ J Pharm Pharmacol; 1998 Mar; 50(3):265-74. PubMed ID: 9600717 [TBL] [Abstract][Full Text] [Related]
12. Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. Damkier P; Hansen LL; Brosen K Br J Clin Pharmacol; 1999 Dec; 48(6):829-38. PubMed ID: 10594487 [TBL] [Abstract][Full Text] [Related]
13. Assessment of cytochrome P450 activity by a five-drug cocktail approach. Zhu B; Ou-Yang DS; Chen XP; Huang SL; Tan ZR; He N; Zhou HH Clin Pharmacol Ther; 2001 Nov; 70(5):455-61. PubMed ID: 11719732 [TBL] [Abstract][Full Text] [Related]
14. Induction of cytochrome P450 (CYP)1A1, CYP1A2, and CYP3A4 but not of CYP2C9, CYP2C19, multidrug resistance (MDR-1) and multidrug resistance associated protein (MRP-1) by prototypical inducers in human hepatocytes. Runge D; Köhler C; Kostrubsky VE; Jäger D; Lehmann T; Runge DM; May U; Stolz DB; Strom SC; Fleig WE; Michalopoulos GK Biochem Biophys Res Commun; 2000 Jun; 273(1):333-41. PubMed ID: 10873607 [TBL] [Abstract][Full Text] [Related]
15. Metabolism of styrene in the human liver in vitro: interindividual variation and enantioselectivity. Wenker MA; Kezić S; Monster AC; De Wolff FA Xenobiotica; 2001 Feb; 31(2):61-72. PubMed ID: 11407535 [TBL] [Abstract][Full Text] [Related]
16. Quinidine as a probe for CYP3A4 activity: intrasubject variability and lack of correlation with probe-based assays for CYP1A2, CYP2C9, CYP2C19, and CYP2D6. Damkier P; Brøsen K Clin Pharmacol Ther; 2000 Aug; 68(2):199-209. PubMed ID: 10976551 [TBL] [Abstract][Full Text] [Related]
17. Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes. Role of CYP3A4. Feierman DE; Lasker JM Drug Metab Dispos; 1996 Sep; 24(9):932-9. PubMed ID: 8886601 [TBL] [Abstract][Full Text] [Related]
18. High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy. VI. Simultaneous evaluation of inhibition potential of drugs on human hepatic isozymes CYP2A6, 3A4, 2C9, 2D6 and 2E1. Bu HZ; Magis L; Knuth K; Teitelbaum P Rapid Commun Mass Spectrom; 2001; 15(10):741-8. PubMed ID: 11344532 [TBL] [Abstract][Full Text] [Related]
19. Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition. Sahi J; Black CB; Hamilton GA; Zheng X; Jolley S; Rose KA; Gilbert D; LeCluyse EL; Sinz MW Drug Metab Dispos; 2003 Apr; 31(4):439-46. PubMed ID: 12642470 [TBL] [Abstract][Full Text] [Related]
20. Changes in cytochrome P450 enzymes by 1,1-dichloroethylene in rat liver and kidney. Hanioka N; Jinno H; Nishimura T; Ando M Arch Toxicol; 1997; 72(1):9-16. PubMed ID: 9458185 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]